Does UnitedHealthcare Cover Jardiance (Empagliflozin)?

The direct answer

Empagliflozin (brand name Jardiance) is an SGLT2 inhibitor tablet approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. UnitedHealthcare commercial and Medicare Advantage plans generally include Jardiance on their formularies, but coverage is conditioned on prior authorization, and the drug typically sits on a mid-range brand tier rather than a generic tier because no FDA-approved generic empagliflozin exists as of this writing. The practical question for most members is not "is it covered" but "which indication is being documented," because a request written for heart failure or CKD is often reviewed differently, and with fewer step-therapy hurdles, than one written for glycemic control alone.

Why formulary tier and PA rules cannot be stated as a single fact

UnitedHealthcare administers many distinct formularies across employer-sponsored commercial plans, individual exchange plans, and Medicare Advantage plans, and each employer group can customize cost-sharing and utilization management within limits. That means a single tier number or copay figure quoted for "UHC" will be wrong for a meaningful share of readers. The safest general statement is that Jardiance is commonly placed as a preferred brand drug on commercial formularies and is frequently subject to step therapy or PA requirements, and Medicare Advantage plans sometimes place it on a higher cost-sharing tier than commercial plans do. The only reliable way to know your own plan's tier, copay, and PA criteria is to check your plan's current formulary document through myuhc.com or to call member services, since formulary documents are updated periodically and last year's tier is not a guarantee of this year's tier.

What prior authorization typically checks for

When a plan requires prior authorization for an SGLT2 inhibitor like Jardiance, the reviewing pharmacy benefit manager is generally trying to confirm that the prescription matches one of the drug's FDA-approved uses and that any plan-specific step therapy has been satisfied or is exempt. Documentation commonly requested across payers, based on typical PBM prior authorization practice for this drug class, includes:

• A confirmed diagnosis matching an FDA-approved indication: type 2 diabetes, heart failure, or chronic kidney disease
• Recent relevant labs or testing (for example, HbA1c for diabetes, an ejection fraction measurement for heart failure, or eGFR and urine albumin data for CKD)
• Documentation of prior diabetes medication trials, when the request is for the diabetes indication
• Prescriber attestation of no contraindication, such as a history of diabetic ketoacidosis

The exact combination of these requirements, and how quickly a decision is issued, is set by the specific plan and its pharmacy benefit manager. Readers should treat the 48-to-72-hour turnaround sometimes quoted for standard PA decisions as a general industry pattern, not a guaranteed UHC timeline, and should ask the prescriber's office or OptumRx directly for the current expected turnaround on a given plan.

Step therapy: what plans commonly expect first

Many commercial plans that use step therapy for SGLT2 inhibitors expect documentation that metformin was tried, or is contraindicated, before approving Jardiance for the type 2 diabetes indication specifically. Common contraindications that can satisfy step therapy without a metformin trial include significantly reduced kidney function, a documented history of lactic acidosis, or GI intolerance that prevented reaching an effective dose.

Heart failure and CKD indications are less consistently subject to diabetes-focused step therapy, because current heart failure guidelines from the American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend SGLT2 inhibitors for heart failure with reduced ejection fraction independent of diabetes status. When a cardiologist or nephrologist documents heart failure or CKD as the indication rather than glycemic control, some plans waive the diabetes-specific step therapy requirement. This is worth raising directly with the prior authorization team if the prescribing rationale is cardiac or renal rather than glycemic, since the request may otherwise be routed through diabetes-focused criteria by default.

Decision framework: which path applies to your prior authorization

Use this to identify which route is most relevant before your prescriber submits the request.

If the prescription is for type 2 diabetes control alone: Expect a metformin step-therapy check. Have your prescriber document exact metformin dose, duration, and the specific reason for discontinuation (not just "intolerance") before submitting, since vague step-therapy notes are a common reason PA requests are sent back for more information.

If the prescription is for heart failure (with or without diabetes): Ask your prescriber to write the diagnosis and ejection fraction findings explicitly and to cite the heart failure indication, not a diabetes indication, on the PA form. This can route the request outside diabetes-specific step therapy rules on some plans.

If the prescription is for chronic kidney disease: Have your prescriber include current eGFR and urine albumin-to-creatinine ratio results dated as recently as possible. CKD-indication PA criteria on some formularies were written before more recent kidney-outcome data existed, so a specialist letter addressing why the CKD indication applies can help.

If you are denied: Request a peer-to-peer review immediately rather than waiting for a formal written appeal. If that fails, file within the plan's stated internal appeal deadline, then pursue external review if the internal appeals are exhausted. Do this in writing and keep copies of every submission and decision letter.

If cost, not coverage, is the barrier: Ask about the manufacturer's savings card if you have commercial insurance, since it cannot be used with Medicare, Medicaid, or Tricare. If you are on a Medicare Advantage plan, ask about the annual Part D out-of-pocket cap and the option to spread costs across the year through the Medicare Prescription Payment Plan.

Evidence behind the indications, and its boundary

The clinical case for prioritizing SGLT2 inhibitor coverage rests on cardiovascular and renal outcome trials for this drug class, not on diabetes control alone. Large randomized cardiovascular outcome trials in patients with type 2 diabetes and established cardiovascular disease have reported reduced cardiovascular mortality with empagliflozin, and a large kidney-outcomes trial reported reduced progression of chronic kidney disease and cardiovascular death with empagliflozin in patients with CKD. These trials are foundational to the drug's heart failure and CKD indications and are commonly cited in payer clinical policies and in prior authorization appeal letters.

That said, the specific effect sizes and confidence intervals from these trials are not restated here with precise numbers, because verifying the exact figures against the primary published trial reports is required before quoting them as fact in a clinical or payer-facing document. A prescriber preparing a PA or appeal letter should pull the exact trial results directly from the peer-reviewed publication or the FDA label rather than from a secondary summary. What is established without needing exact statistics: empagliflozin has FDA-approved indications for type 2 diabetes, heart failure, and chronic kidney disease, and outcome trial evidence in these populations is part of why clinical guidelines recommend the drug class independent of glycemic control. What is not established from the material available here: the exact numeric size of cardiovascular or renal benefit, which should be confirmed against the primary trial publication before it is used in a specific patient's clinical or appeal documentation.

Appeals: the general structure, and what to verify

Health plans, including UnitedHealthcare, are generally required to offer an internal appeal process following a coverage denial, and members who exhaust internal appeals typically have the right to request an external review by an independent review organization not affiliated with the plan. The number of internal appeal levels, exact deadlines for filing, and standard versus expedited review timeframes vary by plan type and by state insurance regulation, so the specific day-counts should be confirmed from your denial letter rather than assumed from a general description. Your denial letter is the authoritative document: it states the clinical rationale for denial, the deadline to appeal, and the process for requesting an expedited review if there is clinical urgency.

Practical elements of a stronger appeal, independent of the exact procedural deadlines: an updated clinical note addressing the specific denial reason, current labs supporting the indication, and, where relevant, a specialist's letter of medical necessity. If the denial cites lack of step therapy, documenting the specific medication, dose, duration, and reason for discontinuation is more persuasive than a general statement of intolerance.

Cost outside and inside coverage

Without insurance, Jardiance is a brand-only drug with no FDA-approved generic as of this writing, so cash pricing is at brand-level cost; check a current pharmacy price or the manufacturer's site rather than relying on a fixed number, since list prices change over time. The manufacturer offers a savings card program for patients with commercial insurance, which can substantially lower the out-of-pocket copay; it explicitly does not apply to patients covered by Medicare, Medicaid, or Tricare, and has its own eligibility and annual benefit limits that should be checked on the manufacturer's page before assuming eligibility.

For UnitedHealthcare Medicare Advantage members, the manufacturer card is not an option, but the Medicare Part D redesign put a $2,000 annual cap on out-of-pocket prescription drug costs starting with the 2025 plan year, and Medicare's payment plan option allows spreading those costs across monthly installments rather than paying them up front. Current details on both the cap and the payment plan option are maintained by CMS at its Inflation Reduction Act Part D improvements page, and this is a regulatory feature that changes as CMS updates guidance, so it is worth checking the current-year figure directly rather than assuming it is unchanged.

Alternatives if Jardiance is denied or unaffordable

Other SGLT2 inhibitors, including dapagliflozin (Farxiga) and canagliflozin (Invokana), carry their own FDA approvals with meaningful overlap in the diabetes, heart failure, and CKD indications, and a specific UHC plan may place one of them on a more favorable tier than Jardiance. Canagliflozin carries a boxed warning regarding increased risk of lower-limb amputation that is not shared by empagliflozin or dapagliflozin, which is a relevant clinical distinction, not just a coverage detail, when a prescriber is choosing among alternatives. Ertugliflozin (Steglatro) is also in the same drug class but has a smaller outcomes-trial evidence base for heart failure and CKD specifically.

If a prescriber believes empagliflozin specifically is clinically preferable to a covered alternative, for example because of a documented adverse reaction to another agent in the class, a formulary exception request explaining that clinical rationale is the correct next step rather than repeated appeals of the original denial.

When this is a decision for your care team, not a coverage question

None of the coverage or appeal process described here changes the clinical decision of whether an SGLT2 inhibitor is appropriate for you. Empagliflozin carries contraindications and monitoring considerations, including risk of diabetic ketoacidosis (which can occur even with normal or only mildly elevated blood glucose), volume depletion, and genital mycotic infections, and it requires individualized dosing and monitoring decisions that should be made with your prescriber, not inferred from an insurance article. Seek urgent care for symptoms such as nausea, vomiting, abdominal pain, unusual fatigue, or difficulty breathing while taking an SGLT2 inhibitor, since these can be signs of ketoacidosis and warrant prompt evaluation regardless of blood glucose level.